Loading page content…
Loading page content…
Loading contract search results…
Loading contract details…
| Source: | Find a Tender Service (FTS) |
| Notice Type: | Tender notice |
| Buyer: | NHS England |
| Main Category: | Services |
| Procurement Method: | Open procedure |
| Submission Methods: | Electronic submission, Written |
Pipeline status
Not addedImports the contract into your BidWriter pipeline · Qualify before you commit to bid
Application Deadline
8 July 2026
34 days left
Estimated Value
£26,136,000
Need help writing this bid?
Our specialists write winning tender responses. Free consultation, no obligation.
Book a free consultation →| Tender Status: | Open |
| Estimated Value (ex. VAT): | £26,136,000 |
| Release Date: | 4 June 2026 |
| Application Deadline: | 8 July 2026 |
| Procurement ID (OCID): | ocds-h6vhtk-06ae08 |
| Notice Reference: | 053026-2026 |
Ready to bid on this contract?
BidWriter AI writes your tender response in minutes — import this contract in one click.
View Original Notice
Access the full notice on the official portal
Onasemnogene abeparvovec intravenous (Zolgensma®) is a one-time, in vivo gene replacement therapy, for use in babies aged 12 months and under, that utilises an adeno-associated virus serotype 9 (AAV9) vector, modified to contain a functional copy of the human SMN1 gene. It is administered intravenously, allowing the vector to deliver the gene into motor neurones and peripheral tissues, enabling the sustained expression of survival motor neuron (SMN) protein, which is deficient or mutated in individuals with SMA.<br/><br/>Onasemnogene abeparvovec intrathecal (OAV101 IT) is a one-time in vivo gene replacement therapy for patients with SMA, proposed to treat individuals with SMA aged 2 years and over. This intrathecal injection will be used to treat a distinct cohort of SMA patients to Zolgensma. It will be assessed via NICE’s technology appraisal programme, with an expected final guidance publication date in late 2026.
Lot 1: Zolgensma only (if no positive NICE recommendation for OAV101 IT)
Lot 2: Positive recommendation for OAV101 IT for paediatric patients (in combination with Lot 1 for Zolgensma)
Lot 3: Positive NICE recommendation for OAV101 IT for adult patients (either standalone or in combination with Lots 1 and 2)
Document pack· 1 file
Published contracts in the last 12 months
1,882
total contracts
£78609.7m
total value
£107,832,301
average contract size
Typical categories
Percutaneous transluminal renal sympathetic denervation for resistant hypertension
NHS England · WAC-606399
NHS National Framework for Etravirine 200mg tablets, Raltegravir 400mg tablets, Ritonavir 100mg tablets
NHS England · WAC-606474
Communication skills for language and interpersonal skills
NHS England · WAC-605845